Raffles Medical Group (BSL) Fundamentals 2026 — P/E 24.7x, Revenue Analysis | SniperIQ
Raffles Medical Group (BSL) is a SG-listed Healthcare company in Medical - Care Facilities with a market capitalization of S
.7B, trading at S$0.94 on the SES. This SniperIQ fundamentals page covers Raffles Medical Group's valuation (P/E 24.7x, P/B 1.7x), profitability (net margin 9.2%), revenue (S$765M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Market CapS
.7B
P/E (TTM)24.7x
Net Margin9.2%
Revenue (FY25)S$765M
Full research coverage
8-Quarter Revenue & Margin Trend
Debt Maturity & Coverage
Peer Valuation Comparison
Free Cash Flow & Owner Earnings
AI Signal + Institutional Flow
DCF Valuation Model
Frequently Asked Questions
What is Raffles Medical Group's market cap?
Raffles Medical Group (BSL) has a market capitalization of approximately S
.7B, trading at S$0.94 on the SES. Market cap moves with the live share price.
What is Raffles Medical Group's P/E ratio?
Raffles Medical Group's trailing twelve-month P/E ratio is 24.7x, with a price-to-book (P/B) of 1.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Raffles Medical Group?
Raffles Medical Group runs a net profit margin of 9.2%, a gross margin of 45.4%, and an operating margin of 11.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Raffles Medical Group generate?
Raffles Medical Group reported revenue of S$765M for fiscal year 2025, with net income of S$71M and earnings per share (EPS) of 0.0381. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Raffles Medical Group pay a dividend?
Raffles Medical Group offers a trailing dividend yield of about 3.2%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Raffles Medical Group financially healthy?
Raffles Medical Group carries a debt-to-equity ratio of 0.08x and a current ratio of 1.31x, with a market beta of 0.21. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Raffles Medical Group a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Raffles Medical Group (BSL) the key facts are: market cap S
.7B, P/E 24.7x, revenue S$765M, 52-week range 0.9-1.09. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Raffles Medical Group's full fundamentals live
Get Raffles Medical Group's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.